Subscribe

MedPlus Health Services Limited (MEDPLUS.NS)

INR806.85 -7.45 (-0.91%)
IN NSE Healthcare Medical - Pharmaceuticals
Address Municipal No: 11-6-56 500072
Hyderabad, IN
CEO Gangadi Madhukar Reddy
Website medplusindia.com
IPO 2021-12-23
ISIN INE804L01022

Explore sections of this company profile

Also trades on Bombay Stock Exchange · MEDPLUS.BO (INR) National Stock Exchange of India · MEDPLUS.NS (INR)
Description

MedPlus Health Services Limited operates primarily as an Indian retailer of pharmaceutical products and diverse general merchandise. Its extensive product catalog includes vital health and wellness items such as prescription medications, vitamins, medical equipment, and diagnostic kits, alongside everyday essentials like toiletries, baby care products, cleaning supplies, and sanitizers. Beyond its retail footprint, the company also offers wholesale cash-and-carry services, comprehensive pathological laboratory testing, and contract manufacturing for its own-brand pharmaceutical goods. By March 31, 2021, MedPlus had established a substantial presence with 1,659 brick-and-mortar stores situated in the Indian states of Karnataka, Tamil Nadu, Telangana, and Andhra Pradesh, complemented by its online store. This Hyderabad-based company was incorporated in 2006.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
INR806.85 -7.45 (-0.91%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
203.4K
Beta
0.43
Float Shares
56.40M
Free Float %
47.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-1.62% -9.49% -2.35% +3.98% +12.16% +9.31% -9.70% +8.53% -21.29% -21.29% -21.29%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
806.85
DCF (Unlevered) 2,543.22 +215.2%
DCF (Levered) 3,036.74 +276.4%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 6 +1
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
5.78
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Pharmaceuticals: +7.8%
    +12.3% ★ Q1'26: +23.5% (vs Q1'25)
  • ✓
    EPS growth Medical - Pharmaceuticals: +20.2%
    +46.1% ★ Q1'26: +24.0% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%
    +3.0% Q1'26: +14.5% (vs Q1'25)
  • ✗
    EBIT margin Medical - Pharmaceuticals: +6.8%
    +4.7% Q1'26: +5.0% (vs Q1'25)
  • ✗
    ROIC Medical - Pharmaceuticals: +6.1%
    +8.8% ★ Q1'26: +10.1% (vs Q1'25)
  • ✗
    Share dilution Medical - Pharmaceuticals: +0.0%
    +0.1% Q1'26: +0.6% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×
    2.35× Q1'26: 2.10× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.43) × ERP
WACC = 88% × Ke + 12% × Kd (8.5%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 2,623.81 Current price: 806.85
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2022
actual 		Mar 2023
actual 		Mar 2024
actual 		Mar 2025
actual 		Mar 2026
6 Rev. Ana.
5 EPS Ana. 		Mar 2027
5 Rev. Ana.
5 EPS Ana. 		Mar 2028
6 Rev. Ana.
5 EPS Ana. 		Mar 2029
2 Rev. Ana.
1 EPS Ana. 		Mar 2030
1 Rev. Ana.
Revenue
37.79B
est: 37.95B (-0.4%)
45.58B
est: 45.62B (-0.1%)
56.25B
est: 58.29B (-3.5%)
61.36B
est: 62.89B (-2.4%)
68.53B
67.16B – 72.10B
+9.0% YoY
78.65B
76.37B – 81.91B
+14.8% YoY
89.92B
86.04B – 97.00B
+14.3% YoY
102.29B
100.47B – 104.11B
+13.8% YoY
117.00B
112.73B – 124.18B
+14.4% YoY
EBITDA
1.87B
est: 1.67B (+11.9%)
1.41B
est: 2.00B (-29.6%)
2.08B
est: 7.88B (-73.5%)
3.24B
est: 8.50B (-61.9%)
9.26B
9.08B – 9.75B
+9.0% YoY
10.63B
10.32B – 11.07B
+14.8% YoY
12.15B
11.63B – 13.11B
+14.3% YoY
13.83B
13.58B – 14.07B
+13.8% YoY
15.81B
15.24B – 16.78B
+14.4% YoY
EBIT
1.63B
est: 1.32B (+23.0%)
960.92M
est: 1.59B (-39.6%)
1.42B
est: 3.54B (-59.8%)
2.50B
est: 3.82B (-34.4%)
4.16B
4.08B – 4.38B
+9.0% YoY
4.77B
4.63B – 4.97B
+14.8% YoY
5.46B
5.22B – 5.89B
+14.3% YoY
6.21B
6.10B – 6.32B
+13.8% YoY
7.10B
6.84B – 7.54B
+14.4% YoY
Net Income
958.02M
est: 1.29B (-25.6%)
497.63M
est: 503.48M (-1.2%)
654.73M
est: 760.50M (-13.9%)
1.50B
est: 1.46B (+3.2%)
2.20B
1.68B – 2.21B
+50.7% YoY
2.59B
1.86B – 2.95B
+17.8% YoY
3.27B
2.59B – 4.76B
+26.5% YoY
5.90B
5.53B – 6.27B
+80.3% YoY
—
— – —
-100.0% YoY
SGA
4.01B
est: 4.37B (-8.3%)
5.57B
est: 5.26B (+5.9%)
6.51B
est: 5.96B (+9.2%)
7.44B
est: 6.43B (+15.8%)
7.00B
6.86B – 7.37B
+9.0% YoY
8.04B
7.80B – 8.37B
+14.8% YoY
9.19B
8.79B – 9.91B
+14.3% YoY
10.45B
10.27B – 10.64B
+13.8% YoY
11.96B
11.52B – 12.69B
+14.4% YoY
EPS
8.55
est: 10.73 (-20.3%)
4.17
est: 3.85 (+8.3%)
5.48
est: 6.35 (-13.7%)
12.57
est: 11.94 (+5.3%)
17.22
13.96 – 18.42
+44.2% YoY
21.78
15.52 – 24.55
+26.5% YoY
32.84
21.55 – 39.63
+50.8% YoY
48.35
46.06 – 52.21
+47.2% YoY
—
— – —
-100.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-26 B 3/5 4/5 4/5 4/5 1/5 1/5 2/5
2026-05-25 B 3/5 4/5 4/5 5/5 1/5 1/5 2/5
2026-05-22 B 3/5 4/5 4/5 5/5 1/5 1/5 2/5
2026-05-21 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-20 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-19 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-18 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-15 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-14 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-13 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-12 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-11 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-08 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-07 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-04 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-22 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-04-16 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
1.13B
OE per share TTM
9.45
Owner's Yield
1.07%
Maintenance CapEx ratio
26.17%
Maint CapEx / Avg PPE
20.6%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 3 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Sophus Capital Emerging Market Small Cap ETF EMSC 0.50% 222.3K 0.85%
2 State Street SPDR S&P Emerging Markets Small Cap ETF EWX 0.04% 266.4K 0.65%
3 WisdomTree India Earnings Fund EPI 0.01% 174.2K 0.84%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
138.6K
Shares Outstanding
120.05M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Sujit Kumar Mahato Chief Financial Officer 20M male
Cherukupalli Bhaskar Reddy Chief Operating Officer & Whole Time Director 12M —
Manoj Kumar Srivastava Head of Corporate Secretarial & Governance, Company Secretary and Compliance Officer 7M male
Gangadi Madhukar Reddy Founder, Chief Executive Officer, MD & Chairman 4M —
Kandasamy Vairaperumal Head of Supply Chain — male
Subrahmanyam Sharma Tatapudi Chief Technology Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Pharmaceuticals